Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 544

1.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators.

Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Erratum in: Lancet. 2019 May 11;393(10184):1936.

PMID:
30995972
2.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

PMID:
30990260
3.

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.

Figtree GA, Rådholm K, Barrett TD, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Neal B.

Circulation. 2019 May 28;139(22):2591-2593. doi: 10.1161/CIRCULATIONAHA.119.040057. Epub 2019 Mar 17. No abstract available.

PMID:
30882240
4.

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.

Matthews DR, Li Q, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Hiatt WR, Nehler M, Fabbrini E, Kavalam M, Lee M, Neal B.

Diabetologia. 2019 Jun;62(6):926-938. doi: 10.1007/s00125-019-4839-8. Epub 2019 Mar 12.

5.

Canagliflozin and Stroke in Type 2 Diabetes Mellitus.

Zhou Z, Lindley RI, Rådholm K, Jenkins B, Watson J, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Shaw W, Oh R, Desai M, Matthews DR, Neal B.

Stroke. 2019 Feb;50(2):396-404. doi: 10.1161/STROKEAHA.118.023009.

6.

Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.

de Jong MA, Petrykiv SI, Laverman GD, van Herwaarden AE, de Zeeuw D, Bakker SJL, Heerspink HJL, de Borst MH.

Clin J Am Soc Nephrol. 2019 Jan 7;14(1):66-73. doi: 10.2215/CJN.04530418. Epub 2018 Dec 17.

PMID:
30559106
7.

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.

de Zeeuw D, Renfurm RW, Bakris G, Rossing P, Perkovic V, Hou FF, Nangaku M, Sharma K, Heerspink HJL, Garcia-Hernandez A, Larsson TE.

Lancet Diabetes Endocrinol. 2018 Dec;6(12):925-933. doi: 10.1016/S2213-8587(18)30289-4. Epub 2018 Nov 6.

PMID:
30413396
8.

Treating diabetic complications; from large randomized clinical trials to precision medicine.

Heerspink HJL, de Zeeuw D.

Diabetes Obes Metab. 2018 Oct;20 Suppl 3:3-5. doi: 10.1111/dom.13418. Review.

9.

Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries.

Eder S, Leierer J, Kerschbaum J, Rosivall L, Wiecek A, de Zeeuw D, Mark PB, Heinze G, Rossing P, Heerspink HL, Mayer G.

Diab Vasc Dis Res. 2019 Jan;16(1):47-56. doi: 10.1177/1479164118795559. Epub 2018 Sep 21.

PMID:
30238781
10.

Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; apost hoc analysis of the PLANET trials.

Idzerda NMA, Pena MJ, Parving HH, de Zeeuw D, Heerspink HJL.

Nephrol Dial Transplant. 2018 Sep 1. doi: 10.1093/ndt/gfy159. [Epub ahead of print]

PMID:
30184238
11.

N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk.

Idzerda NMA, Persson F, Pena MJ, Brenner BM, Brunel P, Chaturvedi N, McMurray JJ, Parving HH, de Zeeuw D, Heerspink HJL.

Diabetes Obes Metab. 2018 Dec;20(12):2899-2904. doi: 10.1111/dom.13465. Epub 2018 Aug 5.

12.

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.

Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Desai M, Li Q, Deng H, Rosenthal N, Jardine MJ, Bakris G, Perkovic V.

Circulation. 2018 Oct 9;138(15):1537-1550. doi: 10.1161/CIRCULATIONAHA.118.035901.

13.

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.

Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, Neal B.

Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704. doi: 10.1016/S2213-8587(18)30141-4. Epub 2018 Jun 21.

14.

Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD.

van den Belt SM, Heerspink HJL, Gracchi V, de Zeeuw D, Wühl E, Schaefer F; ESCAPE Trial Group.

J Am Soc Nephrol. 2018 Aug;29(8):2225-2233. doi: 10.1681/ASN.2018010036. Epub 2018 Jun 21.

PMID:
29930161
15.

How to measure and monitor albuminuria in healthy toddlers?

van den Belt SM, Gracchi V, de Zeeuw D, Heerspink HJL.

PLoS One. 2018 Jun 21;13(6):e0199309. doi: 10.1371/journal.pone.0199309. eCollection 2018.

16.

Baseline characteristics and enrichment results from the SONAR trial.

Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Yi T, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2018 Aug;20(8):1829-1835. doi: 10.1111/dom.13315. Epub 2018 May 1.

17.

Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight.

Koomen JV, Stevens J, Mostafa NM, Parving HH, de Zeeuw D, Heerspink HJL.

Diabetes Obes Metab. 2018 Aug;20(8):2019-2022. doi: 10.1111/dom.13312. Epub 2018 May 1.

18.

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus.

Rådholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B.

Circulation. 2018 Jul 31;138(5):458-468. doi: 10.1161/CIRCULATIONAHA.118.034222.

19.

A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) - Study Design and Baseline Characteristics.

Eder S, Leierer J, Kerschbaum J, Rosivall L, Wiecek A, de Zeeuw D, Mark PB, Heinze G, Rossing P, Heerspink HL, Mayer G.

Kidney Blood Press Res. 2018;43(1):181-190. doi: 10.1159/000487500. Epub 2018 Feb 16.

20.

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.

Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Dey J, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2018 Jun;20(6):1369-1376. doi: 10.1111/dom.13245. Epub 2018 Mar 9.

21.

Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study.

Apperloo EM, Pena MJ, de Zeeuw D, Denig P, Heerspink HJL.

Diabetes Obes Metab. 2018 Jun;20(6):1377-1383. doi: 10.1111/dom.13226. Epub 2018 Feb 20.

22.

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.

Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators.

Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. [Epub ahead of print]

23.

Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy.

Weldegiorgis M, de Zeeuw D, Li L, Parving HH, Hou FF, Remuzzi G, Greene T, Heerspink HJL.

Am J Kidney Dis. 2018 Jan;71(1):91-101. doi: 10.1053/j.ajkd.2017.08.010. Epub 2017 Nov 16.

PMID:
29153995
24.

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).

Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group.

Circulation. 2018 Jan 23;137(4):323-334. doi: 10.1161/CIRCULATIONAHA.117.032038. Epub 2017 Nov 13.

25.

Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial.

Seferovic JP, Pfeffer MA, Claggett B, Desai AS, de Zeeuw D, Haffner SM, McMurray JJV, Parving HH, Solomon SD, Chaturvedi N.

Diabetologia. 2018 Mar;61(3):581-588. doi: 10.1007/s00125-017-4485-y. Epub 2017 Nov 3.

PMID:
29098323
26.

Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.

Petrykiv SI, Laverman GD, Persson F, Vogt L, Rossing P, de Borst MH, Gansevoort RT, de Zeeuw D, Heerspink HJL.

Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1804-1813. doi: 10.2215/CJN.00390117. Epub 2017 Oct 11. Review.

27.

Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

Weldegiorgis M, de Zeeuw D, Dwyer JP, Mol P, Heerspink HJL.

Clin J Am Soc Nephrol. 2017 Oct 6;12(10):1595-1600. doi: 10.2215/CJN.09590916. Epub 2017 Sep 18.

28.

Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.

Webb DJ, Coll B, Heerspink HJL, Andress D, Pritchett Y, Brennan JJ, Houser M, Correa-Rotter R, Kohan D, Makino H, Perkovic V, Remuzzi G, Tobe SW, Toto R, Busch R, Pergola P, Parving HH, de Zeeuw D.

Drugs R D. 2017 Sep;17(3):441-448. doi: 10.1007/s40268-017-0201-0.

29.

Renal trials in diabetes need a platform: time for a global approach?

de Zeeuw D, Heerspink HJL, Jardine M, Perkovic V.

Lancet Diabetes Endocrinol. 2018 May;6(5):356-358. doi: 10.1016/S2213-8587(17)30263-2. Epub 2017 Aug 7. No abstract available.

PMID:
28797748
30.

Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?

Petrykiv S, Laverman GD, de Zeeuw D, Heerspink HJL.

Diabetes Obes Metab. 2018 Jan;20(1):224-227. doi: 10.1111/dom.13057. Epub 2017 Aug 8.

PMID:
28685934
31.

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group.

N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.

32.

ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD.

Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, de Zeeuw D, Eckardt KU, McMurray JJV, Claggett B, Lewis EF, Pfeffer MA.

Am J Kidney Dis. 2017 Oct;70(4):522-531. doi: 10.1053/j.ajkd.2017.04.018. Epub 2017 Jun 7.

PMID:
28599901
33.

The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.

Petrykiv SI, Laverman GD, de Zeeuw D, Heerspink HJL.

Diabetes Obes Metab. 2017 Oct;19(10):1363-1370. doi: 10.1111/dom.12936. Epub 2017 Jun 8.

PMID:
28295959
34.

Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials.

Neal B, Perkovic V, Mahaffey KW, Fulcher G, Erondu N, Desai M, Shaw W, Law G, Walton MK, Rosenthal N, de Zeeuw D, Matthews DR; CANVAS Program collaborative group.

Diabetes Obes Metab. 2017 Jul;19(7):926-935. doi: 10.1111/dom.12924. Epub 2017 Apr 3.

35.

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.

Neal B, Perkovic V, Matthews DR, Mahaffey KW, Fulcher G, Meininger G, Erondu N, Desai M, Shaw W, Vercruysse F, Yee J, Deng H, de Zeeuw D; CANVAS-R Trial Collaborative Group.

Diabetes Obes Metab. 2017 Mar;19(3):387-393. doi: 10.1111/dom.12829. Epub 2017 Jan 25.

36.

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Parving H-H, Lambers-Heerspink H, de Zeeuw D.

N Engl J Med. 2016 Nov 3;375(18):1800-1. doi: 10.1056/NEJMc1611290. No abstract available.

PMID:
28106974
37.

Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes.

Mayer G, Heerspink HJ, Aschauer C, Heinzel A, Heinze G, Kainz A, Sunzenauer J, Perco P, de Zeeuw D, Rossing P, Pena M, Oberbauer R; SYSKID Consortium.

Diabetes Care. 2017 Mar;40(3):391-397. doi: 10.2337/dc16-2202. Epub 2017 Jan 11.

PMID:
28077457
38.

The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.

Pena MJ, de Zeeuw D, Andress D, Brennan JJ, Correa-Rotter R, Coll B, Kohan DE, Makino H, Perkovic V, Remuzzi G, Tobe SW, Toto R, Parving HH, Sharma S, Corringham T, Sharma K, Heerspink HJL.

Diabetes Obes Metab. 2017 May;19(5):749-753. doi: 10.1111/dom.12864. Epub 2017 Feb 22.

PMID:
28019071
39.

Variability in response to albuminuria-lowering drugs: true or random?

Petrykiv SI, de Zeeuw D, Persson F, Rossing P, Gansevoort RT, Laverman GD, Heerspink HJL.

Br J Clin Pharmacol. 2017 Jun;83(6):1197-1204. doi: 10.1111/bcp.13217. Epub 2017 Feb 1.

40.

Comparison of exposure response relationship of atrasentan between North American and Asian populations.

Heerspink HJ, Makino H, Andress D, Brennan JJ, Correa-Rotter R, Coll B, Davis JW, Idler K, Kohan DE, Liu M, Perkovic V, Remuzzi G, Tobe SW, Toto R, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2017 Apr;19(4):545-552. doi: 10.1111/dom.12851. Epub 2017 Jan 27.

PMID:
27981738
41.

Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population-based cohort study.

Meems LM, Brouwers FP, Joosten MM, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, Gansevoort RT, van Gilst WH, van der Harst P, de Boer RA.

ESC Heart Fail. 2016 Sep;3(3):189-197. Epub 2016 Apr 26.

42.

Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease.

Kröpelin TF, de Zeeuw D, Remuzzi G, Bilous R, Parving HH, Heerspink HJ.

J Am Soc Nephrol. 2016 Nov;27(11):3405-3412. Epub 2016 Apr 7.

43.

Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.

Lindhardt M, Persson F, Zürbig P, Stalmach A, Mischak H, de Zeeuw D, Lambers Heerspink H, Klein R, Orchard T, Porta M, Fuller J, Bilous R, Chaturvedi N, Parving HH, Rossing P.

Nephrol Dial Transplant. 2017 Nov 1;32(11):1866-1873. doi: 10.1093/ndt/gfw292.

PMID:
27507891
44.

Blood pressure-lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies.

Olde Engberink RH, Heerspink HJ, de Zeeuw D, Vogt L.

Br J Clin Pharmacol. 2016 Nov;82(5):1351-1357. doi: 10.1111/bcp.13062. Epub 2016 Aug 18.

45.

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease.

Heerspink HJ, De Zeeuw D.

Diabetologia. 2016 Aug;59(8):1621-3. doi: 10.1007/s00125-016-4030-4. Epub 2016 Jun 23. Review. No abstract available.

46.

Unmet need in diabetic nephropathy: failed drugs or trials?

de Zeeuw D, Heerspink HJL.

Lancet Diabetes Endocrinol. 2016 Aug;4(8):638-640. doi: 10.1016/S2213-8587(16)30045-6. Epub 2016 May 6. Review. No abstract available.

PMID:
27160545
47.

Comparison of urine collection methods for albuminuria assessment in young children.

van den Belt SM, Gracchi V, de Zeeuw D, Heerspink HJ.

Clin Chim Acta. 2016 Jul 1;458:120-3. doi: 10.1016/j.cca.2016.04.030. Epub 2016 Apr 27.

PMID:
27129631
48.

Renal endothelial function is associated with the anti-proteinuric effect of ACE inhibition in 5/6 nephrectomized rats.

Vettoretti S, Vavrinec P, Ochodnicky P, Deelman LE, De Zeeuw D, Henning RH, Buikema H.

Am J Physiol Renal Physiol. 2016 May 1;310(10):F1047-53. doi: 10.1152/ajprenal.00325.2015. Epub 2016 Feb 24.

49.

Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome.

Felix Kröpelin T, de Zeeuw D, Holtkamp FA, Packham DK, L Heerspink HJ.

Nephrol Dial Transplant. 2016 Sep;31(9):1471-7. doi: 10.1093/ndt/gfv429. Epub 2016 Jan 19.

PMID:
26790449
50.

Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.

Heerspink HJ, Persson F, Brenner BM, Chaturvedi N, Brunel P, McMurray JJ, Desai AS, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D.

Lancet Diabetes Endocrinol. 2016 Apr;4(4):309-17. doi: 10.1016/S2213-8587(15)00469-6. Epub 2016 Jan 14.

PMID:
26774608

Supplemental Content

Loading ...
Support Center